General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-12 | 2024-02 | 0 | -0.11 | N/A | N/A |
2024-01-16 | 2023-11 | 0 | -0.09 | N/A | N/A |
2023-10-12 | 2023-08 | 0 | -0.07 | N/A | N/A |
2023-08-25 | 2023-05 | 0 | -0.1 | N/A | N/A |
2023-04-14 | 2023-02 | 0 | -0.12 | N/A | N/A |
2023-01-13 | 2022-11 | 0 | -0.12 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2020-10-18 | Aegis Capital | Upgrade | Buy | |
2020-09-03 | Aegis Capital | Upgrade | Buy | |
2020-08-20 | Aegis Capital | Upgrade | Buy | |
2018-12-16 | B. Riley Securities | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-01-26 | BARBIERI ALLEN | Officer and Director | 101.33K | Purchase |
2020-10-04 | CANO FRANCIS R. PH.D. | Director | 152.64K | Stock Gift |
2017-02-26 | CAPITANIO FRANCIS E | President | 87.00K | Sale |
2023-01-25 | COSTE CATHERINE | Director | 43.79K | Purchase |
2018-10-04 | EMERSON JANE | Director | 71.00K | Conversion of Exercise of derivative security |
2023-05-24 | IRANI ZACKARY S | Chief Executive Officer | 1.02M | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Granahan Investment Management LLC | 1.14M | 1.56M | 6.81% |
2023-06-29 | Wasatch Advisors LP | 953.26K | 1.30M | 5.67% |
2023-06-29 | Vanguard Group Inc | 569.96K | 775.15K | 3.39% |
2023-06-29 | Potomac Capital Management, Inc. | 402.92K | 547.97K | 2.40% |
2023-06-29 | Boothbay Fund Management, LLC | 294.38K | 400.36K | 1.75% |
2023-06-29 | Russell Investments Group, Ltd. | 181.69K | 247.09K | 1.08% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | JNL Series Trust-JNL/Multi Manager Small Cap GrowthFd | 611.17K | 831.19K | 3.63% |
2023-06-29 | Wasatch Micro-Cap Value Fund | 482.56K | 656.28K | 2.87% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 398.34K | 541.74K | 2.37% |
2023-06-29 | Vanguard Extended Market Index Fund | 168.20K | 228.75K | 1.00% |
2023-07-30 | USAA Mutual Fund Tr-Small Cap Stock Fund | 117.69K | 155.36K | 0.70% |
2023-06-29 | Clearwater Select Equity Fund | 88.91K | 120.92K | 0.53% |
Split | Date |
---|---|
1 : 1 | 2016-04-07 |
1 : 2 | 1994-11-14 |
ROI can you post the link to the source with the CE mark
$BMRA RSI is cooling down, will retest 10 before noon.
$BMRA ROI, I will enjoy watching you squeeze.
$BMRA here comes the squeeze even without news. wait for the squeeze with actual news.
$BMRA Grossly oversold. Bounce inevitable.
$BMRA is exempt from the shelter in place order. It is deemed essential within the meaning of the executive order and its production of kits is unaffected.
See page 2, subheading 1
https://covid19.ca.gov/img/EssentialCriticalInfrastructureWorkers.pdf
$BMRA does not need to obtain EUA and can immediately engage in commercial sales since March 16
$BMRA manufactures it’s own tests. It has facilities in both Ir, California and another production facility in Mexico.
$BMRA’s test is now EUA-exempt, the FDA changed the EUA policy on March 16, 2020 to exempt serum antigen tests only.
No other serum antigen test is produced in the USA or by an American manufacturer. $BMRA is the only manufacturer currently producing Covid-19 serum antigen tests in the USA. It has filed provisional patents for this test.
$BMRA has obtained more than eight patents in the past ten years for similar tests in the United States.
$BMRA has obtained both FDA and CE approval for at least 12 different tests that it manufactures for other diseases.
The only other company able to offer a Covid-19 serum antigen test in the United States is $AYTU which is a reseller of Chinese tests. You cannot compare the profit margin of $AYTU and $BMRA - it is absurd
$BMRA is mentioned here: